International Cancer Conference Journal最新文献

{"title":"Rapidly progressive and fatal drug-induced interstitial pneumonitis after three cycles of enfortumab vedotin plus pembrolizumab treatment for metastatic urothelial carcinoma: a case report.","authors":"Yuya Iwamoto, Kojiro Tashiro, Takaaki Kitayama, Yuki Takiguchi, Yusuke Andoh, Fumihiko Urabe, Zenya Saito, Takahiro Kimura","doi":"10.1007/s13691-025-00837-z","DOIUrl":"https://doi.org/10.1007/s13691-025-00837-z","url":null,"abstract":"<p><p>Enfortumab vedotin, an antibody-drug conjugate, in combination with pembrolizumab (PEM) (EVP), has become a standard first-line regimen for patients with locally advanced or metastatic urothelial carcinoma (la/mUC). Although this combination demonstrates superior survival outcomes compared with platinum-based chemotherapy, interstitial pneumonitis has been reported in up to 10% of cases. Acute, fatal presentations, however, are exceedingly rare. We report the case of a 78-year-old man with mUC and asymptomatic interstitial lung disease, identified on baseline chest computed tomography (CT), who developed rapidly progressive and fatal drug-induced interstitial pneumonitis after three cycles of EVP. His comorbidities included diabetes mellitus, obesity, and hypertension. On day 17 of the third cycle, he presented with dyspnea, and CT of the chest demonstrated diffuse bilateral ground-glass opacities. Despite the prompt initiation of high-dose corticosteroids and broad-spectrum antimicrobials, respiratory failure progressed rapidly, and the patient died 5 days after symptom onset. Compared with prior studies, the clinical course was exceptionally fulminant and refractory to treatment. Advanced age, poorly controlled diabetes mellitus, obesity, and pre-existing interstitial lung disease may have contributed to the severe outcome, emphasizing the need for careful patient selection and rigorous respiratory monitoring when administering EVP.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s13691-025-00837-z.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 1","pages":"166-169"},"PeriodicalIF":0.5,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12831737/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146051958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Conversion surgery following nivolumab plus SOX therapy for unresectable advanced esophagogastric junction cancer: two case reports with perioperative genomic profiling.","authors":"Ko Ikegame, Hayato Omori, Masao Hada, Tomomi Oka, Tastunori Nadaya, Hideki Watanabe, Atsushi Takano, Ayako Kimura, Masayuki Inoue, Kazusige Furuya, Yuji Iimuro, Kenji Amemiya, Yosuke Hirotsu, Hitoshi Mochizuki, Ryosuke Tajiri, Masao Omata","doi":"10.1007/s13691-025-00838-y","DOIUrl":"https://doi.org/10.1007/s13691-025-00838-y","url":null,"abstract":"<p><p>Nivolumab plus SOX chemotherapy has emerged as an effective first-line treatment for HER2-negative unresectable advanced gastric cancer, and conversion surgery following favorable treatment response is increasingly considered as a potential curative strategy. Here, we report two cases of HER2-negative esophagogastric junction cancer initially diagnosed as unresectable. Case 1 presented with splenic metastasis and tumor thrombus in the splenic vein, and Case 2 with multiple liver metastases and extensive lymph node involvement. Both cases were classified as cStage IVB. After receiving nivolumab plus SOX chemotherapy, they demonstrated significant tumor shrinkage and disappearance of distant metastases, making CS feasible. Robotic gastrectomy was successfully performed in both cases. Pathological examination revealed tumor downstaging in both, while Case 1 showed neuroendocrine carcinoma and Case 2 revealed mucinous and signet-ring cell carcinoma components. Genomic profiling before and after treatment demonstrated persistence of <i>TP53</i> mutation in Case 1 and <i>SYNE1</i> mutation in Case 2, with no significant changes in allele frequency. These findings suggest that while therapy-sensitive clones were eliminated, resistant clones remained. Nivolumab plus SOX chemotherapy may help make conversion surgery possible in patients with HER2-negative advanced gastric cancer. Analyzing treatment-resistant tumor characteristics pathologically and genomically could support the development of personalized therapies.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s13691-025-00838-y.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 1","pages":"170-174"},"PeriodicalIF":0.5,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12831739/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146051815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NTRK-rearranged soft tissue sarcoma that originated from the head and neck with a robust response to the TRK inhibitor larotrectinib.","authors":"Nakano Kenji, Oki Ryosuke, Wang Xiaofei, Nakao Takehiro, Fukuda Naoki, Urasaki Tetsuya, Ono Makiko, Tomomatsu Junichi, Miura Yuji, Sato Yukiko, Yamashita Kyoko, Takeuchi Kengo, Hayashi Naomi, Fukada Ippei, Mitani Hiroki, Takahashi Shunji, Kenji Nakano","doi":"10.1007/s13691-025-00832-4","DOIUrl":"https://doi.org/10.1007/s13691-025-00832-4","url":null,"abstract":"<p><p>Targeted therapy for <i>NTRK</i> fusion gene-positive solid tumors has been approved as tumor-agnostic, but the frequency of such tumors is extremely low (~ 1%-2%). The same is true of soft-tissue sarcoma (STS), but STS includes some histologic types with high rates of <i>NTRK</i>-fusion positivity such as infantile fibrosarcoma. <i>NTRK</i>-rearranged spindle cell neoplasm is newly defined in the current WHO classification (5th edition), and there is thus relatively high motivation to search for <i>NTRK</i>-fusion in STS patients depending on the background. We report the case of a 31-year-old Japanese female with no remarkable history and an NTRK fusion-positive STS with a head and neck primary tumor who was successfully treated with targeted therapy. She was referred to our hospital due to a maxillary gingival tumor that had rapidly increased over the past several months. At her referral, the patient's previous pathological review revealed (by FISH) that the <i>NTRK</i> fusion gene was positive. We performed a pathological review and close examination with a view to introducing a TRK inhibitor. The patient was refractory to standard chemotherapy and radiotherapy. Concurrent comprehensive genome profiling (FoundationOne^® CDx) confirmed the <i>LMNA-NTRK1</i> fusion, and treatment with the TRK inhibitor larotrectinib was started. With larotrectinib treatment, the tumor shrank in size at an early stage, and the response has been maintained for > 2 years.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 1","pages":"147-153"},"PeriodicalIF":0.5,"publicationDate":"2025-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12831764/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146051930","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expanding the clinical impact of precision oncology.","authors":"Noriomi Matsumura","doi":"10.1007/s13691-025-00835-1","DOIUrl":"https://doi.org/10.1007/s13691-025-00835-1","url":null,"abstract":"","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"14 4","pages":"351"},"PeriodicalIF":0.5,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12696203/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145756638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction: Mitomycin, 5-fluorouracil, and radiotherapy for anal canal cancer in a patient undergoing hemodialysis: a case report.","authors":"Yuki Ozawa","doi":"10.1007/s13691-025-00830-6","DOIUrl":"10.1007/s13691-025-00830-6","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1007/s13691-025-00821-7.].</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 1","pages":"65"},"PeriodicalIF":0.5,"publicationDate":"2025-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12831779/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146051888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HER2 reassessment triggered by comprehensive genomic profiling reveals a therapeutic opportunity in refractory gastric cancer: a case report.","authors":"Takaaki Iwado, Yoshiyasu Kono, Motoyuki Otsuka","doi":"10.1007/s13691-025-00827-1","DOIUrl":"https://doi.org/10.1007/s13691-025-00827-1","url":null,"abstract":"<p><p>We present a case of advanced gastroesophageal junction adenocarcinoma initially diagnosed as Human epidermal growth factor receptor 2 (HER2)-negative based on immunohistochemistry (IHC) of a metastatic lymph node biopsy. The patient developed progressive disease despite multiple lines of systemic chemotherapy. Comprehensive genomic profiling (CGP) performed on archived primary tumor tissue revealed high-level <i>ERBB2</i> amplification. Reassessment of HER2 status using IHC on the primary tumor confirmed strong HER2 overexpression (IHC 3+). Based on this finding, the patient was treated with trastuzumab plus FOLFOX followed by trastuzumab deruxtecan (T-DXd), achieving a durable response. Notably, the esophageal stricture caused by cervical lymphadenopathy resolved completely, and the patient remained progression-free for over 21 months with T-DXd therapy. This case highlights the clinical significance of intratumoral HER2 heterogeneity and underscores the importance of reassessing biomarkers in patients with refractory disease. It also illustrates the potential role of CGP in identifying overlooked therapeutic targets and guiding subsequent treatment decisions in gastric cancer. CGP may serve as a useful adjunct to conventional diagnostics, particularly when initial testing is inconclusive or based on metastatic tissue.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 1","pages":"133-137"},"PeriodicalIF":0.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12831736/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146051951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adult Wilms tumor in an eighty-year-old man: A case report and literature review of recent elderly-onset cases.","authors":"Juna Nishio, Tatsuo Kanda, Hideo Sakuma, Tatsuru Hashimoto, Hirohito Kakinuma, Wataru Kenjo, Yasushi Teranishi","doi":"10.1007/s13691-025-00829-z","DOIUrl":"https://doi.org/10.1007/s13691-025-00829-z","url":null,"abstract":"<p><p>Wilms tumor primarily occurs in children and is extremely rare in adults, with very limited reports. No standardized diagnostic pathway or treatment protocol exists for adult Wilms tumor, especially in elderly patients. We present a case of an 80-year-old man who presented with appetite loss and abdominal bloating, and was diagnosed with WT1-positive Wilms tumor on the basis of contrast-enhanced computed tomography and biopsy findings, including immunohistochemical analysis. Palliative radiation therapy was initiated. However, the tumor rapidly progressed, and the patient died shortly. Autopsy revealed a large mass around the right kidney with multiple organ metastases, and histology confirmed an unfavorable type. To clarify its clinical features, we reviewed the literature dating back to 1975 through PubMed and identified 11 reported cases of patients aged 70 years or older. More than half had an unfavorable histology, and only three survived more than one year after treatment. There were four cases of surgical or treatment-related mortality. Although pediatric protocols, such as the National Wilms Tumor Study, are recommended for adult cases, application in elderly patients remains challenging. Strategies tailored to this population are needed, taking into account poor prognosis as well as comorbidities and performance status.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 1","pages":"126-132"},"PeriodicalIF":0.5,"publicationDate":"2025-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12831710/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146051729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prostatic artery pseudoaneurysm presenting with hematuria following robot-assisted radical prostatectomy: a case report.","authors":"Sotaro Kayano, Ken Shibata, Eriko Nishi, Yohei Tubouchi, Hideaki Kanazashi, Keiji Sakurai, Tatsuya Shimomura, Kazuki Akieda, Takahiro Kimura","doi":"10.1007/s13691-025-00824-4","DOIUrl":"https://doi.org/10.1007/s13691-025-00824-4","url":null,"abstract":"<p><p>Pseudoaneurysm following robot-assisted radical prostatectomy is an infrequent complication. We present a rare case of gross hematuria caused by a pseudoaneurysm. A 76-year-old man was diagnosed with prostatic adenocarcinoma and underwent robot-assisted radical prostatectomy. On postoperative day 9, he presented with gross hematuria and clot retention, accompanied by anemia. Bladder irrigation was performed, resulting in improvement of the hematuria. Contrast-enhanced computed tomography revealed a pseudoaneurysm. As his hematuria improved and his vital signs remained stable, angiography was performed on postoperative day 10. This revealed a pseudoaneurysm arising from the prostatic artery, which was successfully treated with transcatheter arterial embolism. His postoperative course was uneventful, and he was discharged on postoperative day 14. Pseudoaneurysm after robot-assisted prostatectomy is rare but important to consider in patients with delayed hematuria. Early diagnosis and embolization can lead to good outcomes.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 1","pages":"103-107"},"PeriodicalIF":0.5,"publicationDate":"2025-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12831785/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146051913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carboplatin monotherapy in recurrent uterine leiomyosarcoma with homozygous BRCA2 deletion: a case report.","authors":"Takafumi Ujihira, Yukiko Namba, Sumire Ishii, Toshiyuki Okumura, Koyo Yoshida, Shintaro Makino","doi":"10.1007/s13691-025-00825-3","DOIUrl":"https://doi.org/10.1007/s13691-025-00825-3","url":null,"abstract":"<p><p>Uterine leiomyosarcoma (ULMS) is a rare gynecological malignancy with a high recurrence rate and poor prognosis. No standard treatment exists for recurrent cases. Recent studies indicate that homozygous BRCA2 deletion may serve as a therapeutic target in non-BRCA-associated malignancies, including ULMS. Here, we report a 49-year-old woman with recurrent BRCA2-deficient ULMS who responded to carboplatin monotherapy. Although PARP inhibitors have been utilized in BRCA-mutated ULMS, this case underscores the potential efficacy of platinum-based chemotherapy as an alternative treatment strategy. Furthermore, a therapeutic approach integrating platinum-based chemotherapy followed by PARP inhibitor maintenance, similar to that employed in platinum-sensitive ovarian cancer, warrants further investigation.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 1","pages":"108-113"},"PeriodicalIF":0.5,"publicationDate":"2025-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12831702/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146051868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Two cases of metastatic colorectal cancer in which epidermal growth factor receptor gene amplification benefited from panitumumab monotherapy.","authors":"Taro Sato, Fumio Nagashima, Naohiro Okano, Mariko Nishioka, Masato Hayashi, Yuji Saito, Tadakazu Hisamatsu, Shuichi Hironaka","doi":"10.1007/s13691-025-00826-2","DOIUrl":"https://doi.org/10.1007/s13691-025-00826-2","url":null,"abstract":"<p><p>Panitumumab, an anti-epidermal growth factor receptor (EGFR) antibody, is a standard drug used in patients with <i>RAS</i> wild-type (WT) metastatic colorectal cancer (mCRC). Studies have reported that the <i>KRAS</i> mutation is a negative predictive biomarker; however, <i>EGFR</i> gene amplification may be a predictive biomarker for the response to anti-EGFR antibodies. We encountered two patients with <i>EGFR</i> gene amplification (one with <i>KRAS</i> mutation) who responded to panitumumab monotherapy after failure of standard chemotherapy. Case 1 was an 85-year-old woman with <i>RAS</i> WT transverse colon cancer with liver metastases. After receiving capecitabine monotherapy as first-line therapy, S-1 plus irinotecan plus bevacizumab therapy as second-line, trifluridine/tipiracil (FTD/TPI) monotherapy as third-line, and regorafenib monotherapy as fourth-line therapy, the patient received panitumumab monotherapy as fifth-line therapy. After that, comprehensive gene panel testing showed <i>EGFR</i> gene amplification. This therapy continued for 6.9 months without progressive disease (PD), and liver metastases shrank by up to 72%. Case 2 was a 65-year-old man with <i>RAS</i> WT (initially) sigmoid colon cancer and multiple liver metastases. After receiving mFOLFOX6 plus panitumumab therapy as first-line therapy, FOLFIRI plus bevacizumab as second-line, he underwent conversion surgery. After 3 months, multiple liver metastases were detected on CT scan, then, comprehensive gene panel testing was done, and it showed high tumor mutational burden (TMB) and <i>EGFR</i> amplification. As third-line therapy, he received pembrolizumab monotherapy. After PD for pembrolizumab, OncoBEAM™ was done and it showed neo-<i>RAS</i> mutation. Regardless of that result, panitumumab was resumed as a fourth-line treatment and administered for 5.2 months without PD; liver metastases shrank by up to 50%. We encountered two patients with mCRC and <i>EGFR</i> gene amplification who responded to panitumumab monotherapy. <i>EGFR</i> gene amplification may be a potential biomarker for anti-EGFR antibodies, regardless of <i>RAS</i> status.</p>","PeriodicalId":13703,"journal":{"name":"International Cancer Conference Journal","volume":"15 1","pages":"114-120"},"PeriodicalIF":0.5,"publicationDate":"2025-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12831776/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146051960","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}